NRIX Form 4: 50,000 director options at $12.52, vesting over 36 months

Rhea-AI Filing Summary

Nurix Therapeutics (NRIX) reported a director stock option grant on a Form 4. The filing shows 50,000 options to purchase common stock at an exercise price of $12.52, granted on November 6, 2025, with an expiration date of November 6, 2035.

The option vests as to 1/36 of the total shares monthly beginning December 6, 2025 until fully vested on November 6, 2028, subject to continued service. Ownership is reported as Direct.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DANSEY ROGER D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 50,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DANSEY ROGER D

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1700 OWENS STREET

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$12.52	11/06/2025		A		50,000		(1)	11/06/2035	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The stock option vests as to 1/36 of the total shares monthly beginning December 6, 2025 until the option is fully vested on November 6, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Roger Dansey	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nurix Therapeutics (NRIX) disclose in this Form 4?

A director was granted 50,000 stock options with an exercise price of $12.52 per share.

When do the NRIX director stock options vest?

They vest 1/36 monthly starting December 6, 2025 and are fully vested by November 6, 2028.

What is the exercise price and expiration for the NRIX options?

The exercise price is $12.52, and the options expire on November 6, 2035.

How many shares underlie the reported NRIX stock options?

The options cover 50,000 shares of common stock.

What is the reported ownership form for these NRIX options?

The filing lists ownership as Direct.

Who is the reporting person on the NRIX Form 4?

The signature block identifies Roger Dansey, with an attorney-in-fact signing.